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Primary ciliary dyskinesia (PCD) is a chronic suppurative airways disease that is usually recessively inherited and
has marked clinical phenotypic heterogeneity. Classic symptoms include neonatal respiratory distress, chronic
rhinitis since early childhood, chronic otitis media, recurrent airway infections leading to bronchiectasis, chronic
sinusitis, laterality defects with and without congenital heart disease including abnormal situs in approximately
50% of the cases, and male infertility. Lung function deteriorates progressively from childhood throughout life.
‘Better Experimental Approaches to Treat Primary Ciliary Dyskinesia’ (BEAT-PCD) is a network of scientists and
clinicians coordinating research from basic science through to clinical care with the intention of developing
treatments and diagnostics that lead to improved long-term outcomes for patients. BEAT-PCD activities are
supported by EU funded COST Action (BM1407). The third BEAT-PCD conference and fourth PCD training school
were held jointly in February 2018 in Lisbon, Portugal. Presentations and workshops focussed on advancing the
knowledge and skills relating to PCD in: basic science, epidemiology, diagnostic testing, clinical management and
clinical trials. The multidisciplinary conference provided an interactive platform for exchanging ideas through a
program of lectures, poster presentations, breakout sessions and workshops. Three working groups met to plan
consensus statements. Progress with BEAT-PCD projects was shared and new collaborations were fostered. In this
report, we summarize the meeting, highlighting developments made during the meeting.
Keywords: Primary ciliary dyskinesia, Chronic respiratory disease, MultidisciplinaryIntroduction
Primary Ciliary Dyskinesia (PCD) is a multi-organ
genetic disease associated with bronchiectasis, chronic
rhinosinusitis, male infertility and situs inversus (SI)
[1]. The estimated incidence in Europe is generally
1:10,000 [2, 3], but it can be much more common in
isolated or consanguineous populations, such as the
Dutch Volendam, where the incidence is 1:400. In
health, motile cilia in the respiratory tract clear
pathogen-laden mucus from the airways. Impaired* Correspondence: jlucas1@soton.ac.uk
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(http://creativecommons.org/publicdomain/zemucociliary clearance, caused by abnormal ciliary
function, leads to persistent upper and lower respira-
tory tract symptoms starting at birth [4, 5] and with
time leads to bronchiectasis [6] and impaired lung
function [7]. Sperm flagella have a similar ultrastruc-
ture to cilia and most but not all men with PCD are
infertile [8]. In the early embryo, motile nodal cilia
control the establishment of left-right asymmetry; ap-
proximately half of PCD patients exhibit situs inver-
sus totalis (SIT) while 6-12% have situs ambiguus
(SA), which is often associated with complex congeni-
tal cardiac defects [4]. To date there are no specific
treatments for PCD, and hence no evidence based
guidelines for clinical management of patients.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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Ciliary Dyskinesia’ (BEAT-PCD; COST Action BM1407)
is a network of scientists and clinicians coordinating
research from basic science through to clinical care,
with the intention of developing treatments and diag-
nostics to improve long-term outcomes for people with
PCD (www.BEATPCD.org). Within the first 30 months
we have united a multidisciplinary network of 257
participants from 27 countries to collaborate through
training schools, visits between institutions and confer-
ences [9, 10]. This report covers the proceedings of the
3rd Annual BEAT-PCD Conference and 4th Annual
Training School, held in Lisbon in February 2018, which
included state-of-the-art lectures, oral presentations,
workshops, a trainee networking forum and a poster
session.
Workshops at previous BEAT-PCD meetings had
identified and prioritised research projects; for ex-
ample, a multinational study of the natural variability
of spirometry values (PROVALF-PCD), the effects of
nutritional status and a review of experimental
models of PCD. BEAT-PCD clinicians have written an
expert statement for the management of children with
PCD [1], and work groups (WGs) continue to develop
consensus guidelines for specific aspects of diagnosis
and management, such as diagnosis via transmission
electron microscopy (TEM), infection control, a defin-
ition for pulmonary exacerbations and physiotherapy
management. An active Training School within the
BEAT-PCD network promotes education, training and
career development to its 110 junior members.
Interaction between senior academics, clinicians,
students, post-doctoral fellows and invited speakers
from academia and industry at conferences, work-
shops and Training Schools provides career develop-
ment opportunities.Work group activities during the conference and training
school
BEAT-PCD activities are coordinated by four collabora-
tive WGs: basic science, epidemiology, clinical care and
clinical trials (Fig. 1).
WG1 (basic science) aims include highlighting recent
scientific advances that will translate into clinical re-
search and ultimately clinical practice. Plenary talks ad-
dressed the concepts and mechanisms underlying
left-right patterning in the early embryo; mucus compos-
ition and how it affects mucociliary transport; and po-
tential small molecule therapies that can alter mucus
composition and therefore may be able to alter mucus
clearance. WG1 held workshops on the nature of lateral-
ity and on model organisms that can be used in PCD
research.WG2 (epidemiology) presented information from
the international PCD (iPCD) cohort and PCD regis-
try [11, 12]. The iPCD cohort grows exponentially
and currently consists of 3507 patients from 20 coun-
tries and 26 centres. Several recent studies nested in
the iPCD cohort were presented. The PCD registry is
now part of the European Reference Network (ERN),
more specifically the ERN-LUNG network. Countries
outside the EU can also be part of the ERN-LUNG
network and contribute with data on PCD patients.
Another project within WG2, 3 and 4 is the develop-
ment of a standardized PCD Proforma for patient
follow-up and prospective data collection, as pre-
sented by Myrofora Goutaki.
WG3 (clinical care) ran workshops discussing consen-
sus statements on infection prevention and control for
PCD patients, and defining respiratory exacerbations (in
partnership with WG4). A research study looking at the
differences in delivery of care for PCD across Europe
aims to investigate variations in models of service deliv-
ery for patients with suspected or confirmed diagnosis of
PCD within and between European countries. The Inter-
national PCD Physiotherapy Network (IPCDPN) pre-
sented plans to publish a consensus statement on
“Effective physiotherapy” for PCD patients during the
coming year.
WG4 focuses on developing clinical trials for PCD,
with two currently underway [13–15]. Presentations
were given on research that aims to improve outcome
measures available in PCD trials. Age -appropriate qual-
ity of life measures, first developed in the BESTCILIA
project (FP7) are now being further validated and trans-
lated by the BEATPCD network [16–18]. Workshops
were held on biomedical imaging techniques as potential
outcome measures in PCD.
State-of-the-art lectures
Plenary lectures were given by keynote speakers on topics
relevant to BEAT-PCD including left-right asymmetry,
super-resolution imaging to support PCD diagnostics, and
mucus disorders which might mimic PCD.
Three plenary lectures focussed on explaining the
mechanisms underpinning left-right (L-R) patterning.
Dominic Norris (UK) explained how the L-R axis is
fundamental in visceral organ patterning and place-
ment. He emphasised the importance of standardizing
the nomenclature used to describe heterotaxia, for ex-
ample avoiding the usage of situs solitus (SS) with
isolated organ situs defects, e.g. situs solitus with dex-
trocardia should be more properly referred to as situs
ambiguous or heterotaxy. Finally, he gave an overview
of L-R establishment in human embryos. He focused
199 the heart is severely affected by L-R patterning
defects, namely its highly asymmetric anatomy. The
Fig. 1 A diagrammatic representation of the aims of work groups within BEAT-PCD and COST action-associated activities. WG = work group
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anatomy require clear and appropriate early left-right
signalling, to enable their correct temporal and spatial
activation [19].
Leonor Saúde (Portugal) elaborated on the history of
our understanding of how left and right are first estab-
lished in the embryo and on how this varies between dif-
ferent species. Some rely on cilia-driven flows (mice,
rabbit, fish and Xenopus), while others utilise cell move-
ments to convert symmetrical into left-right asymmetric
gene expression patterns (e.g. chicken). Downstream of
ciliary motility in the embryo, the Nodal-Lefty-Pitx2
gene cascade is expressed on the left but not right sideof the organism in the majority of bilaterians; organisms
with chiral asymmetries, such as snails, also use this
genetic cascade.
Adam Shapiro (Canada) spoke about laterality defects
in patients with PCD from a clinical perspective. He de-
fined the spectrum of situs abnormalities [20], explaining
that congenital heart disease with heterotaxy is 200-fold
higher in PCD patients than in the general population
[21]. A recent prospective study found laterality defects
in 55% of PCD cases [22]. Clinical outcome in patients
with PCD and heterotaxy has been reported to be worse
than in those with PCD alone, without heterotaxy [23].
To fully evaluate the presence of heterotaxy, abdominal
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were advised to be included in the diagnostic work-up
for PCD.
Following on from more conceptual presentations
about super-resolution microscopy (SRM) at 2017’s
BEAT-PCD Conference [9], Sharon Dell and Vito
Menella (Canada) presented a study exploring the use of
these techniques in PCD diagnosis. Three-dimensional
structured illumination microscopy (SIM) quantification
and stochastic optical resolution microscopy (STORM)
imaging were evaluated in a two-arm study exploring
whether diagnostic specificity could be improved. These
techniques showed increased specificity compared to
transmission electron microscopy (TEM) and immuno-
fluorescence (IF). SRM analysis can be automated to re-
duce subjectivity and is faster than diagnosis using a
combination of IF and TEM. STORM reveals the de-
tailed structures of ciliary proteins and thus may be
beneficial in difficult diagnostic cases.
David Thornton (UK) discussed the importance of
mucus in physiological airway function and the clin-
ical implications of mucus disorders. Gel-forming mu-
cins (MUC5AC and MUC5B) make up the main
structural components of the protective mucus barrier
in the airways. In mouse lungs, MUC5B [24] expres-
sion predominates during homeostasis. Muc5b null
mice show deficient mucociliary clearance and re-
duced survival compared to wild-type. MUC5AC has
been found to be crucial for heterogeneous mucus
plugging, a component of airway hyper-reactivity in
asthma [25]. Inflammation increases the elasticity of
mucus by stimulating the secretion of stored mucins,
thereby increasing their relative concentration. More-
over, inflammatory signalling cascades lead to an in-
crease in reactive oxygen species, which promote
mucin cross-link formation [26] and further increase
mucus elasticity. Strategies for tackling mucus ob-
struction of airways were introduced, including restor-
ing mucus hydration and reducing mucin levels.
Oral presentations
A number of short oral presentations on PCD research
were given throughout the conference.
Basic sciences oral presentations
The scientific presentations primarily included reports of
novel PCD causative genes identified within the last year.
Ewa Zietkiewicz (Poland) presented on the genetic
screening of PCD mutations in the Polish/Slavic popu-
lation. Classical and next generation sequencing in 377
families determined the population-specific profile of
the three most frequently mutated PCD-causing genes
(SPAG1, CCDC39, CCDC40); some of these mutations
had not previously been described in Europeanpopulations. The study also identified a novel candidate
PCD gene, C11orf70. Nasal brushing samples from pa-
tients showed absence of cilia motility and lack of outer
and inner dynein arms. Knocking down c11orf70 in
zebrafish resulted in defective ciliary motility. Protein
truncating mutations found in the Polish cohort sug-
gest that MNS1 could be another PCD candidate gene.
Inga Höben (Germany) also reported on the role of
C11orf70 in PCD. She explained that C11orf70 is expressed
in nasal biopsies as well as differentiated primary human air-
way cell cultures, consistent with a role in motile ciliogenesis.
Inga demonstrated that patients with C11orf70 mutations
exibit immotile cilia and sperm flagellae, and that these both
lack inner and outer dynein arms, implicating C11ORF70 in
cytoplasmic pre-assembly of dynein arms. Immunofluores-
cent staining of patient cilia showed reduction of dynein
heavy chains, whilst no effect was seen on other ciliary struc-
tures (such as radial spokes and nexin links).
Hannah Farley (UK) presented analysis of ciliary motil-
ity in the trachea and embryonic node of Pierce1-/- mice,
which are known to exhibit situs defects [27]. By quanti-
fying embryonic nodal ciliary motility, Hannah demon-
strated that the laterality defects resulted from
dyskinetic ciliary beating and disrupted flow in the em-
bryonic node. She further described reduced beat fre-
quency and aberrant beat pattern in tracheal cilia. TEM
showed that tracheal cilia have a ultrastructural defects
most similar to those seen in patients with CCDC103
mutations, suggesting a role for PIERCE1 in the assem-
bly of dynein arms. Motility analyses of sperm flagella in
Pierce1-/- mutant mice are ongoing.
Priyanka Anujan (UK) also focused on Pierce1, specific-
ally on its role in motile ciliogenesis. Pierce1 expression is
upregulated during mucociliary differentiation of primary
tracheal and nasal epithelial mouse cells. Enriched expres-
sion of Pierce1 was observed in mouse organs containing
motile cilia (lungs, testes, brain, ovary), along with other
cilia motility genes (Foxj1, Tekt1). Studies of two zebrafish
pierce1 models delivered contradicting results: pierce1
morphants showed severe situs abnormalities and curved
body axis, typically associated with cilia defects, while a
proportion of CRISPR-Cas9-induced mutants showed
only mild situs abnormalities.
Sandra Cindric (Germany) reported homozygous STK36
(serine-threonine kinase 36) loss-of-function mutations in
a PCD patient with situs solitus (SS), relatively high nNO
(240ppb) and a stiff ciliary beat pattern with reduced amp-
litude [28]. The gene has been previously shown to be in-
volved in motile ciliogenesis and cilia orientation in
Drosophila and the mammalian oviduct [29, 30], and
STK36 mutations lead to impaired cilia orientation in hu-
man epithelial cells. Immunofluorescence staining indi-
cated that STK36 was essential for assembly of central
pair components and that it interacted with radial spoke
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axoneme.
David Hoogewijs (Switzerland) reported on androglo-
bin (ADGB), a recently identified oxygen-binding pro-
tein. ADGB is strongly conserved across evolution and
its expression is specific to the testis, where it is impli-
cated in postmeiotic spermatogenesis and is essential for
male reproduction [31]. A proportion of Adgb-knockout
mice developed signs of PCD (hydrocephalus after birth,
mucus accumulation, and congenital heart defects). The
congenital heart defects observed are not typical
situs-related defects, but instead myocardial hyper-
trophy; other defects not associated with PCD, such as
polycystic kidney disease (PKD), were also observed.
This diverges from the typical phenotype of mice null
for causative PCD genes (situs defects, hydrocephalus).
Mahmoud Fassad (UK) presented a targeted NGS
(next generation sequencing) programme aimed at
identifying causative PCD mutations. A cilia-specific,
multi-gene panel has been established to analyse 180
PCD patient families, and has identified nearly 80% of
the causative mutations. Mutation distribution showed
a population-specific profile, with different modal genes
involved in each ethnic group (European cohort:
DNAH5, DNAH11; Arab cohort: CCDC39, CCDC40;
South Asian cohort: LRRC6, CCDC103). Two novel
PCD candidate genes (C11orf70 and DNAH9) were
identified in this study, and the effect of knocking these
down in Paramecium was also presented.
Pedro Sampaio (Portugal) reported an innovative study
to determine when left-right pattern is established in the
zebrafish embryo. Using mechanical manipulation to
inactivate the left-right organizer, he defined a temporal
window during which a directional fluid flow in the or-
ganizer is required. He showed that development of
thoracic visceral organs (e.g. heart) and abdominal
visceral organs (e.g. liver) is initiated at the same time
point, and is coordinated by the same signalling path-
ways (Nodal-Lefty-Pitx2 cassette), leading to similar pro-
portions of visceral and abdominal organ laterality
defects.Clinical oral presentations
Florian Halbeisen (Switzerland) presented on the evolu-
tion of PCD diagnostic testing in Europe among 2822
patients of the iPCD cohort. The proportion of PCD pa-
tients tested with nasal NO (nNO), electron microscopy
(EM) and high-speed video microscopy analysis (HSVA)
were assessed. Results were compared by laterality status
and the period of diagnosis (before or after the 2009
consensus statement from the European Respiratory So-
ciety [32]). Patients with laterality defects had fewer tests
performed than patients with situs solitus. The use ofnNO (73% vs 62%) and HSVM (81% vs 71%) was lower
in patients with laterality defects, while EM testing (82%
vs 83%) stayed the same. This suggests that in patients
with laterality defects are more often directly tested with
EM. Overall, there was poor adherence to the 2009 con-
sensus recommendations, with heterogeneity in diagnos-
tic testing between countries.
Hannah Mitchison (UK) reported the prevalence of
laterality defects and discussed the underlying clinical
and genetic risk factors in a cohort of 389 PCD patients
attending the management service in the UK.
Of all patients studied, 199 had a genetic diagnosis
and 370 had a confirmed situs status through clinical
imaging (surveying SS, SIT and SA). Out of the 370, 234
patients fulfilled the criteria required for having their
organ defects classified and from this it was calculated
that 17% had congenital heart defects (CHD), rising to
25% having CHD and/or organ defects other than SIT–
much higher than previous estimates. Risk factors for
CHD were found to include having a situs defect and
having consanguineous parents.
A subset of nine genes (RSPH1, RSPH4A, RSPH9,
HYDIN, CCDC164, CCDC65, CCNO, MCIDAS, RPGR)
where mutations have not previously been associated
with situs abnormalities in PCD patients was presented.
A phenotypic continuum concerning PCD and CHD
was suggested, as a pathogenic missense mutation in a
known PCD gene (DNAAF1) was found to cause CHD
with clinical evidence of PCD. Woolf Walker (UK) pre-
sented a study assessing body mass index (BMI) and
bioimpedance spectroscopy (BIS) measurements in a co-
hort of 40 PCD patients under 16 years old attending
University Hospital Southampton. Data on clinical
phenotype, anthropometric measurements and nutri-
tional intake of the patients were also collected. The
study concluded that early nutritional intervention may
have a positive impact on clinical outcome measures,
and that monitoring of vitamin D may be important in
PCD patients.
Andreia Pinto (Portugal) presented an overview of
PCD diagnostics in Portugal and emphasized the need
for further development in the Portuguese diagnostic
network. She also highlighted progress made, especially
in the identification of ultrastructural abnormalities in
patients, and discussed the correlation between hall-
mark ultrastructural defects and ciliary beat pattern
studied by HSVA.
Panayiotis K. Yiallouros (Cyprus) presented the pulmon-
ary lobectomy as a clinical intervention using data from
2855 patients in the iPCD cohort. 163 lobectomized pa-
tients from 14 European PCD diagnostic centres were
identified. The prevalence of lobectomy was higher in
adult than in paediatric patients. In a nested case control
study, lobectomized patients had worse lung function and
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compared to other patients in the iPCD cohort. They also
reported that female gender and multiple lobectomies
were associated with poorer prognosis and long-term out-
comes. Participants discussed that it was not possible to
know whether the patients who underwent lobectomy had
worse lung disease than those who had not, and therefore
whether the surgery itself was responsible for poor
outcome.
Farheen Daudvohra (UK) presented a study on the
relationship between the genetic variants and struc-
tural phenotype of outer dynein arms (ODA) using
tomography to produce high-resolution 3D models of
ciliary axonemal microtubular doublets and ODA vol-
ume ratios. They identified mutations associated with
ODA structure in 39% of a cohort of 195 patients ge-
notyped using NGS, in known PCD genes and a can-
didate gene; DNAH9. In patients with mutations in
DNAH9, they found a significant deficiency in the
ODA volume at the distal aspect when compared to
the proximal aspect of the axoneme reflecting the
DNAH9 protein positioned in the distal part of the
cilia. It was concluded that use of 3D electron tomog-
raphy can detect subtle changes in the ultrastructure
of ODA in PCD patients.
Ongoing and new BEAT-PCD projects
Several ongoing BEAT-PCD projects are in different
stages of development or implementation, and an update
on each was presented by the lead in each project. New
members at the conference were encouraged to join and
participate in these projects to widen the network of
international collaborations.
Myrofora Goutaki (Switzerland) discussed the develop-
ment of a disease-specific proforma as a tool for stand-
ardizing longitudinal data collection and follow-up care
for patients with PCD. Recording clinical signs and
symptoms in PCD is highly subjective and there is a
wide variability in definitions and assessment [4]. The
standardized proforma was developed through an
adapted Delphi approach and was designed to capture
information at different stages of the disease. It includes
basic medical information, physical examination of lungs
and heart, ENT examination, growth measurements,
lung function measurements and other clinical tests,
hospitalisations and treatment, interim medical history
and information regarding lifestyle and environment. It
is expected to improve the quality of collected data for
better clinical care as well as prospective research. In
addition it will allow easier communication and data ex-
change in a standardized way between collaborating cen-
tres. The next step is to pilot the proforma in both
paediatric and adult populations, and to incorporate it in
the database used for the iPCD cohort.Bruna Rubbo (UK) presented an update on the
PROVALF-PCD study (Prospective Observational multi-
centre study on Variability of Lung Function in stable
PCD patients). The study is using spirometry measures
to monitor the natural intra-individual and inter-
individual variability of FEV1 z-scores in stable PCD
patients. In addition, the variability of spirometry mea-
sures before and after pulmonary exacerbations will be
evaluated.
Recruitment for the study is ongoing, and will end in
April 2018. Seven centres are already active, and 91 pa-
tients have already been recruited. Patients will be
followed up until May 2019 and spirometry measure-
ments will be recorded at each clinic visit every 3-6
months, using a study-specific database.
Lynne Schofield (UK) presented an update on the
international PCD physiotherapy network (IPCDPN).
The IPCDPN aims to develop evidence-based prac-
tices and further collaborations for an international
physiotherapy consensus document. A European sur-
vey has already been conducted to identify physio-
therapists advising PCD patients on airway clearance.
As a result, a physiotherapy network was set up in
Basecamp, and teleconferences have been held to dis-
cuss future projects.
A manuscript on standard of care for physiotherapists,
discussing the English national physiotherapy guidelines
for children with PCD and covering areas such as service
standards, airway clearance techniques, mucolytics and
muco-active agents, exercise, and sinonasal management
is in press.
ERN-Lung PCD CORE
Heymut Omran (Germany) presented the structure and
highlighted the benefits of being part of the EU-funded
ERNs (European Reference Networks) for rare complex
diseases; with emphasis on the PCD CORE of the ERN
for Respiratory Diseases (ERN-Lung). These networks
aim to improve patient care and epidemiological know-
ledge of rare diseases through creating centralized and
highly specialised care centres, Europe wide collection of
data, sharing of agreed clinical standards, and the devel-
opment of strong collaborations between the ERN cores.
The integral role of the PCD registry was highlighted,
which is a continuation of the PCD Registry set up
during the 7th Framework Programme (FP7) funded
research project BESTCILIA [12]. This allows data to be
stored centrally and utilised in different research
projects. Proposed projects include: exploration of
genotype-phenotype correlations; correlation of nNO
production rates in molecularly defined PCD individuals;
correlation of lung function parameters with other
ERN-Lung Cores; variation of lung function parameters
among siblings; exploration of microbiological results in
Farley et al. BMC Proceedings 2018, 12(Suppl 16):64 Page 7 of 15PCD cohort; and a new consensus group for IF
microscopy.
Healthcare providers applying for either full or sup-
porting membership for the PCD CORE must meet the
minimal requirements, which include the availability of
key diagnostic tests and specialised treatments. Recruit-
ment of new EU healthcare providers for patients with
PCD is still needed and he emphasised that it will be
easier for institutions affiliated with ERN to apply for EU
funding, including ERN-specific funding opportunities.
Revisiting BESTCILIA
BESTCILIA was an FP7 funded research programme
which preceded BEAT-PCD.
Claudia Kuehni (Switzerland) presented the results of
the observational trials in the iPCD cohort, which is
now a BEAT-PCD adopted study and currently has
3507 PCD patients in 20 countries [11]. In 2017, the
methods and first results of the iPCD cohort were pub-
lished in the European Respiratory Journal [11], along-
side a paper on growth and nutritional status and their
association with lung function [33]. Further work using
the iPCD cohort dataset is underway. During the con-
ference, Florian Halbeisen (Switzerland) reported on
lung function in PCD patients, and Panayiotis Kouis
(Cyprus) presented a nested study in 20 centres on lob-
ectomies from the iPCD cohort. Myrofora Goutaki
(Switzerland) is investigating neonatal manifestations,
and Florian Halbeisen (Switzerland) is evaluating the
evolution of diagnostic testing of PCD in Europe.
Planned studies will be focused on the clinical picture
and national history of PCD, phenotypes, and the cre-
ation of a simple disease classification model. Data on
symptoms, morphology and genetics will be added to
the iPCD cohort to be used for future publications. The
standardised PCD proforma will be linked to the iPCD
cohort database and will provide further prospective
clinical data on patients from centres that use it. The
iPCD is a dynamic cohort – it is still possible for new
centres to join, for participating to add more patients,
and to add follow-up data on patients already
registered.
Heymut Omran (Germany) presented the international
PCD registry which is now part of the ERN-LUNG net-
work [12]. The ERN-LUNG network is based on the ex-
change of expertise and clinical data on patient cases
through the network with specific technical solutions.
One of these technical solutions is the Data Warehouse
for safe data storage and data analysis. Patients can
register themselves in the international PCD registry for
eligibility checks to participate in clinical trials. Both
European and non-European countries can join this net-
work as full or supporting members, respectively. The
international PCD registry can help to improve highlyspecialised patient-centred cross-border care and can be
linked with other ERN-LUNG Cores, including ERN-
LUNG networks for cystic fibrosis (CF) and for non-CF
bronchiectasis.
Panayiotis Kouis (Cyprus) presented an update on stan-
dardized diagnostic PCD testing in European countries with
limited health care resources. A 24-month patient recruit-
ment cycle in Cyprus, Greece, and Poland was initiated for
diagnostic testing. Training workshops took place in
Muenster, Athens, Krakow, and Limassol. Publications from
this work package have included a meta-analysis dedicated
towards diagnostic accuracy of nasal nitric oxide for estab-
lishing diagnosis of PCD [34]; a systematic review and
meta-analysis on prevalence of PCD in consecutive referrals
of suspect cases and the TEM detection rate [35]; and an
international cross-sectional study on PCD [36]. Currently, a
manuscript describing the development of an evidence-
based diagnostic algorithm for PCD work-up is in
preparation.
Jane Lucas (UK) presented updates on the develop-
ment, validation, and translation of measures to assess
Quality of Life in patients with PCD (QOL-PCD). These
age-specific questionnaires were first developed in Eng-
lish and then translated into German, Dutch and Danish
with cross-culturally validation. The questionnaires have
now been translated into 10 languages. QOL-PCD was
developed for children, teenagers, and adults with PCD,
and for parents of children with PCD [17, 18] and then
underwent psychometric validation [16]. The QOL-PCD
questionnaires are free to use after the copyright holders
have approved. Future actions of the QOL project in-
cludes a grant application for Parental Impact question-
naires for children aged <6 years.
Helene Kobbernagel (Denmark) presented the progress
of the first multinational Randomized Controlled Trial
(RCT) on Azithromycin in PCD. This double-blind, parallel
group study examined the efficacy and safety of azithromy-
cin maintenance therapy for 6 months in subjects with
PCD. The primary outcome of this RCT is pulmonary
exacerbations in patients with PCD. A total of 90 subjects
were included from Rigshospitalet in Denmark,
Copenhagen, VU Medical Center Amsterdam, Netherlands,
University Hospital Muenster, Germany, Royal Brompton
Hospital and University Hospital Southampton, United
Kingdom, and Inselspital Bern, Switzerland. Data are being
cleaned, processed, and locked in an electronic case report
form (CRF) for further statistical analyses and unblinding of
treatment allocation. The study protocol, rationale and re-
cruitment of the Azithromycin trial has been published
[14]. Several manuscripts are planned including assessing
safety and efficacy of azithromycin maintenance therapy in
PCD as well as associations between QOL-PCD outcomes
and clinical measures such as spirometric values and lung
clearance index derived from multiple breath washout.
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Transition for patients with PCD
Amanda Harris (UK) and Amanda Friend (UK) led a
workshop that explored the concept of patient transition
between paediatric and adult care using the “Ready
Steady Go” Programme [37]. Data from UK centres
show that patients with PCD have a higher adherence to
treatment and better outcomes when they are appropri-
ately transitioned to adult care. The Ready Steady Go
Programme offers both tick-box proformas to make sure
that healthcare professionals cover every necessary point
and a more flexible approach, allowing individually
based communication. The programme provides a plat-
form for open exchange between patients and healthcare
professionals by providing the time and opportunity to
explore concerns that the patient might otherwise not
feel comfortable to express.
Pre-clinical models for investigating PCD
Susana Lopes (Portugal), Dominic Norris (UK) and
Monica Bettencourt-Dias (Portugal) led a workshop on
pre-clinical models. The workshop was focussed on
informing participants about range of model organisms
suitable for use in PCD research. Different models that
exhibit motile cilia and can be used to investigate PCD
were discussed. Unicellular organisms included Parame-
cium, Chlamydomonas and Trypanosoma, whilst Pla-
naria and Drosophila were suggested as invertebrate
models. Zebrafish, Xenopus and mouse were given as
examples of vertebrate models. The strengths and weak-
nesses of each organism as a PCD model were
highlighted, and how different research objectives and
experimental design influence the choice of model or-
ganism that a researcher might make. Researchers were
advised to consider both the aims of their research and
practical constraints such as time, budgetary require-
ments and skill set required for different model organ-
isms when evaluating which could best aid their work.
Physiotherapy – education, techniques and tailoring a
programme for patients with PCD
Paulo Buonpensiero (Italy) and Lue Philipsen (Denmark)
facilitated a workshop on physiotherapy, focusing on key
aspects of physiotherapy for PCD patients. The aim of
this workshop was to highlight the many considerations
needed to develop an effective and individualized
physiotherapy regimen. The physiological principles of
different techniques were explained. Important points
for the selection of physiotherapy technique included:
underlying pathology; the physiology of the airways; age
of the patient; patient preference of technique; severity
of disease; and level of compliance of the patient. Finally
they discussed how clinicians can improve the effective-
ness and efficiency of airways clearance techniques byensuring that the airways are in their optimal physical
state prior to doing physiotherapy. For instance, the use
of mucolytics, a good inhalation technique and an effect-
ive inhalation device will improve the physical state of
the airways by improving their hydration, reversing any
bronchoconstriction and reducing irritation of the air-
ways. Therefore, these preparation techniques could as-
sist secretion clearance.
Nasal brushing techniques and how to process samples for
the diagnostic pathway
Sarah Ollosson (UK), Amelia Shoemark (UK), Claire
Jackson (UK) and Rob Hirst (UK) led a workshop on
nasal brushing techniques and the diagnostic pathway.
They educated the participants on how to take a good
nasal brushing biopsy and recognise an adequate sample
by HSVA. The main focuses of the practical session were
how to prepare the media and brushes, how to prepare
and position the patient and contraindications of the
test. The talk summarised: how to prepare samples for
HSVA, cell culture, immunofluorescence and fixation for
TEM; how to recognize features of an adequate sample
by light microscopy; and factors that may affect sample
quality.
Laterality in PCD
This workshop was facilitated by Leonore Saúde (Spain),
Susana Lopes (Portugal) and Dominic Norris (UK). The
underlying mechanisms controlling left-right patterning
were discussed, enabling a detailed and in-depth exam-
ination at the evolutionary conservation and divergence
of laterality patterning. Group discussion of the nature
of laterality defects observed in PCD patients followed,
with situs randomisation being of particular interest.
The facilitators emphasised that ciliary motility defects
at the embryonic node lead to randomisation of situs,
which explains the range of laterality defects observed in
PCD patients.
Future prospects for cross-sectional imaging in PCD: can we
build on conventional CT and is there a role for MRI?
The workshop was led by Tom Semple (UK). The first
part of the workshop focused on the fundamentals of
conventional imaging and included an interactive discus-
sion about the principles of chest x-ray and computed
tomography (CT). In the second part of the workshop,
structural magnetic resonance imaging (MRI) was dis-
cussed, including comparisons on the different charac-
teristics and uses of MRI and CT. Scoring sheets have
limitations as they are time consuming, have significant
inter-reader variability, require training and depend on
sub-scores and reporting of composite scores. Quantita-
tive imaging techniques were also discussed, including
semi-quantitative visual scoring and mapping techniques
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mains a research tool and there are no disease-specific
scoring systems for CT; however, imaging is an active
area of research at many centres and it is hoped that
standardised approaches for imaging the PCD lung will
evolve in the near future.
Nasal nitric oxide in the diagnostic workup of PCD
The workshop was facilitated by Jane Lucas (UK), Claudia
Kuehni (Switzerland), Bruna Rubbo (UK) and Amanda
Harris (UK). Claudia discussed how to identify patients
for diagnostic testing. The positive predictive value of
nNO measurements within a specialised PCD diagnostic
centre is 44% but this falls to 0.6% if measurements are
taken with general pulmonology settings where the rate of
false positives will be proportionately much higher. The
PICADAR tool [38] and Leigh score [39] for clinical diag-
nosis of PCD were also discussed, as were the ERS Task
Force recommendations of diagnostic nNO use [40]. A
series of case vignettes facilitated discussion of the advan-
tages and disadvantages of each diagnostic test, as well as
the recommendations of which procedure is to be used
for nNO measurement according to patient age. The
workshop finished with hands-on nNO measurement
experience.
Clinical trials in PCD
The workshop was facilitated by Kim G Nielsen
(Denmark) and Helene Kobbernagel (Denmark). The aims
of PCD treatment and a brief examination of current clin-
ical non-evidence based options were discussed. The facil-
itators then gave an overview of current trials and
summarised clinical outcome measures that have been or
are being used in PCD. Participants analysed design of
these trials, including exclusion and inclusion criteria. The
necessity of including multiple centres in a PCD trial was
discussed, as were the implications this may have for trial
design. Participants were divided into two groups consist-
ing of mixed scientific and clinical backgrounds for an
interactive conversation on study designs, and then had
the opportunity to design their own randomised clinical
trial. One group considered a study concerning inhalation
of dornase alfa and the other drafted a study on use of in-
haled antibiotic for chronic pulmonary infection with
Pseudomonas Aeruginosa.
Patient education following a new diagnosis of PCD
Gemma Marsh (UK), Laura Baynton (UK) and Fiona
Copeland (UK) facilitated a workshop focusing
post-diagnosis patient education. The facilitators pre-
sented an overview of the patient education programme
at the Royal Brompton Hospital, London. The discussion
revolved around explaining PCD to a newly diagnosed
patient or parent and the impact the diagnosis mighthave in their lives, as well as patient management of
their condition and the importance of complying with
treatment. The facilitators gave practical tips and pre-
sented examples of patient case studies to help partici-
pants to understand the patient’s perspective on
receiving a PCD diagnosis. Fiona Copeland shared her
own experiences as a parent of two children with PCD.
Consensus Statement Workshops
Transmission electron microscopy: hallmark defects
European diagnostic guidelines recommend ‘a hall-
mark defect’ in TEM as a confirmatory diagnostic test
for PCD [41]. However, there is currently no inter-
national classification of ultrastructure for cilia biop-
sies and there is considerable heterogeneity among
pathology reports describing PCD. Thirteen invited
attendees representing nine countries met for the sec-
ond time to develop a consensus statement for
reporting ciliary ultrastructure by TEM for PCD diag-
nosis. Aims for the consensus guidelines include de-
fining hallmark defects diagnostic for PCD; defining
what should be included in a TEM report to assist
multidisciplinary diagnosis of PCD; and defining ad-
equacy of a diagnostic sample.
During the workshop experts discussed the results
to date and the draft manuscript. The group planned
a final Delphi survey for two items on which 80%
consensus had not yet been reached and drew up a
strategy to test the guideline before publication. A
final face to face meeting is planned at the next
BEAT-PCD conference.
Infection control
The development of a consensus statement for PCD and
cross infections was initiated at the previous BEAT-PCD
Training School and Conference [9] at a workshop
chaired by Helle Krogh Johansen (Denmark) and Kim G
Nielsen (Denmark).
An e-survey was circulated to the group prior to the
meeting raising questions regarding infection prevention
and control in PCD, including microbiology measures
and treatment strategies to prevent cross-infections in
out-patient and in-patient settings. Participants dis-
cussed the survey responses and concluded that add-
itional surveys need to be taken before a formal
agreement can be achieved.
Defining pulmonary exacerbations
The inaugural BEAT-PCD Conference in 2015 identified
the need for a consensus statement to define pulmonary
exacerbations in children and adults with PCD as an
outcome measure for clinical trials. Paediatric and adult
pulmonologists, along with a nurse, physiotherapist and
patient representatives have completed three rounds of
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2017 to develop the definition. The results of these sur-
veys were discussed at this conference, with fine-tuning
of the wording of some of the items. It concluded that
one or two further e-surveys will be needed before the
final definition is agreed and presented at the next
BEAT-PCD conference.Short Term Scientific Missions
Short term scientific missions (STSMs) provide an op-
portunity for early stage researchers (ESRs) to visit a re-
search institution in another country, with the aims of
sharing knowledge and skills between centres. This is
intended to advance PCD research at their institution
and to develop collaborative projects. Developing PCD
centres can also use STSMs to invite an expert to pro-
vide on-site training and expertise. Up to fifteen bursar-
ies are awarded each year. More information on STSM
applications can be found on the BEAT-PCD website
(http://www.beatpcd.org/).
During this Conference and Training School, STSM
participants presented overviews of their experience dur-
ing their visit.
Nuria Camats (University Hospital Vall d'Hebron, Barcelona)
visited Heymut Omran in Münster, Germany. During
her 2-week stay, she gained experience on how to
perform genetic analysis of PCD-related genes. She
also received hands-on training regarding IF micros-
copy of ciliated respiratory epithelial cells. She plans
to apply these new skills to improve the accuracy of
diagnostics and to develop candidate-variant func-
tional studies in her home institute.
Margarita Kaliva (University of Cyprus) also visited
Heymut Omran in Münster. She gained experience and
training on how to establish an ALI- culture system,
which she will implement in her home institute.
Joe Hayes (University of Leicester, UK) was invited as
an expert to visit the University Hospital Vall d'Hebron,
Barcelona, and was hosted by Antonio Moreno Gald.
During his visit, he shared his experience of IF in PCD
diagnosis using a panel of ciliary protein markers
(DNAH5, DNALI1, RSPH4A and GAS8), and on cell
culture including ALI technique. In Barcelona he per-
formed IF microscopy on PCD patients and healthy con-
trols and assisted the host centre in establishing
ALI-culture.
Loretta Müller (University of Bern, Switzerland) was
hosted by Jane Lucas at the PCD diagnostic centre in
Southampton UK. More specifically, she was introduced
to IF and ALI techniques as well as training in HSVA.
She received an overview of the organization and struc-
ture of the PCD diagnostic centre, and aims to establish
a comprehensive diagnostic service at her home centre.Pierrick le Borgne (University Paris-Saclay, France) visited
Hannah Mitchison at University College London, UK.
Through a collaboration with Mahmoud Fassad (UK), he
performed RNAi gene silencing of C11orf70 in Parame-
cium, and analysed Paramecium swimming velocity, ciliary
beat frequency and pattern, and ultrastructure by TEM.
Poster session
The BEAT-PCD Conference and Training School in-
cluded a poster session. Titles and authors are given in
Table 1, with permission. Abstracts are presented in Part
2 [link].
Difficult case management discussions
The management of PCD patients remains challenging,
with limited evidence base to guide clinicians on best
practice [1, 42]. Discussion of difficult clinical cases is
therefore key to further developing expert consensus on
management. Five such challenging cases were presented
during this interactive session.
Cases presented included:
Eric Haarman (Netherlands) presented a 9 year old
boy with bi-allelic DNAH5 mutations, who has had sig-
nificant clinical decline, with seasonal variation. Bron-
choscopy revealed copious sticky mucus but culture of
the bronchial lavage was negative. He received hyper-
tonic saline, maintenance oral and regular intravenous
antibiotics. The audience suggested further investiga-
tions for infection specifically for nontuberculous
mycobacteria by use of selective media and for fungal
infection, including investigating for allergic bronchopul-
monary aspergillosis, and also considering co-
morbidities such as asthma. The audience advised
continuing aggressive management with close follow-up.
Nisreen Rumman (Palestine) presented a case of sib-
lings from a consanguineous marriage with bronchiec-
tasis, clubbing, hepatosplenomegaly and leucopenia.
PCD diagnostic workup was normal, as were metabolic/
haematological and enzymatic investigations. Whole ex-
ome sequencing revealed a mutation in STXBP2, which
confirmed Familial Hemophagocytic Lymphohistiocyto-
sis. The siblings were referred for bone marrow trans-
plant. This highlights the importance of seeking
alternative diagnoses to PCD, as therapies differ and
may be curative.
Julie Duncan (UK) presented three cases from the
Royal Brompton Hospital:
 Case 1 had PCD phenotype with respiratory
symptoms and dextrocardia, low nNO and cilia
beating at the tip but static at the base. TEM and IF
were normal (genetics pending). The patient
developed seizures and was diagnosed with
neurofibromatosis (NF) type 1. A possible
Table 1 Poster titles presented by authors (country of first author) at the 3rd BEAT-PCD Conference
Poster title Authors (country of first author)
Is there a defect in ENaC activity in the nasal epithelium of
patients with PCD?
Harman K, Alton EWFW, Davies JC, Waller MD, Crowley S (UK)
Ciliary functional analysis using videomicroscopy: time for a
standardisation
Kempeneers C, Seaton C, Espinosa BG, Chilvers (Belgium)
Loss-of-function mutations in PIHD3 cause X-linked PCD with
outer and inner dynein arm defects
Hoben I, Paff T, Loges NT, Aprea I, Wu K, Bakey Z, Haarman EG, Daniels JMA,
Sistemaans EA, Bogunovic N, Dougherty GW, Große-Onnebrink J, Matter A,
Olbrich H, Werner C, Pals G, Schmidts M, Omran H, Micha D (Germany)
Increased plasma ceramide and sphingomyelin levels in the
plasma of PCD patients
Topcu DB, Tugcu G, Ozcan F, Aslan M, Esref S, Hizal M, Yalcin E, Ersoz D,
Ozcelik U, Kiper N, Lay I, Oztas Y (Turkey)
The role of laterality signals from the left-right organiser in
zebrafish gut patterning
Bota C, Lopes S (Portugal)
Downstream target of Pkd2 affects nodal signalling regulator
in left-right development.
Jacinto R, Lopes S (Portugal)
ENKUR- a novel heterotaxy gene Menchen T, Sigg MA, Lee C, Jungnickel MK, Dougherty GW, Pennekamp P,
Florman HM, Wallingford JB, Reiter JF, Omran H (Germany)
Successful pregnancies for six women with PCD Sivaramakrishnan H, Cottee A, Coon C, Morgan L (Australia)
Two siblings with PCD and hepatic involvement Hizal MG, Bilgic E, Taskiran E, Atilla P, Akcoren Z, Gunaydin O, Ozen H, Esref S,
Emiralioǧlu N, Yalcin E, Ersoz D, Kiper N, Yuce A, Ozcelik U (Turkey)
Homozygous loss-of-function mutations in MNS1 cause
laterality defects and male infertility
Hjeij R, Ta-Shma A, Perles Z, Dougherty GW, Abu Zahira I, Letteboer SJF,
Antony D, Darwish A, Mans DA, Spittler S, Edelbusch C, Cindric S, Menchen T,
Olbrich H, Stuhlmann F, Aprea I, Pennekamp P, Loges NT, Breuer O, Shaag A,
Rein AJJT, Gulec EY, Gezdirci A, Abitbul R, Elias N, Amirav I, Schmidts M,
Roepman R, Elpeleg O, Omran H (Germany)
Creation of a Danio rerio mutant using CRISPR-Cas9 as a
model system to study PCD.
Rasteiro M, Lopes S (Portugal)
Continence assessment in paediatric patients with PCD Wilkins H, Friend A, Harris A, Keenan V (UK)
A new possible role of V-ATPase in the left-right
development
Pestana S, Lopes S (Portugal)
Immunofluorescence is a useful adjunct to TEM for
diagnosis of PCD
Canoy I,MacKenney K, Clarke C, Morgan L, Buddle L, Hughes L (Australia)
A four-year experience of a PCD diagnostic centre in
Greece
Chatzipirasidis G, Douros K, Mpoutopoulou B, Papadopoulos M, Grammeniatis V,
Dimakou K, Priftis KN (Greece)
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was two diseases in one patient, was discussed. No
one else in the audience had experience of a co-
existence of these two conditions.
 Case 2 was siblings demonstrating a severe
phenotype, with stiff dyskinetic ciliary beating by
HSVA and GAS8 was absent by IF. Genetics
revealed mutations in CCDC164. The audience
agreed that these patients suffered from a more
severe disease progression. Possible predictors of
lung function decline were discussed. The
importance of genotype/phenotype association
studies was raised and agreed upon by the
audience.
 Case 3: A patient with PCD and persistent right
middle lobe consolidation requiring bronchoscopy
had developed a pneumothorax after the procedure.
The group agreed that pneumothorax is not
expected to be more common in patients with PCD
compared to other disease groups.Difficult diagnostic cases
Despite recent evidence-based guidelines for the diagno-
sis of PCD, many cases remain inconclusive [40, 41, 43].
Accurate diagnosis of subtle cases requires experience,
and yet PCD diagnosis is not always clear even in refer-
ence centres. Discussion of complicated cases across
centres is therefore important.
Carolina Constant (Portugal) presented two cases with
inconclusive diagnoses:
Case 1: An 8 year old, who was born at term and ad-
mitted to NICU due to aspiration pneumonia, presented
with ongoing respiratory symptoms, and left lower lobe
collapse leading to a lobectomy. PCD diagnostics re-
vealed a PICADAR score of 6 [38], low nNO, clusters of
cells on TEM but no cilia observed, minor microtubule
abnormalities with many inflammatory cells giving the
impression of infection. The audience advised to repeat
TEM, lack of cilia commonly being a secondary problem
caused by infection. Mutations in CCNO or MCIDAS
can be primary causes of reduced motile cilia.
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tion, developed bronchiolitis obliterans following
adenoviral infection at 14 months of age. Now 12
years old, he presented with ongoing respiratory
symptoms and ear infections, clubbing, reduced lung
function and diffuse bilateral bronchiectasis on CT
with small airways involvement. PCD work-up dem-
onstrated a PICADAR score of 6 [38], normal nNO,
TEM with some cilia with partial ODA defects, and
HSVA revealing normal CBF but with stiff movement.
The audience advised a repeat of TEM and to per-
form IF.
Claire Jackson (UK) and Rob Hirst (UK) presented
cases of patients with CCDC103 mutations. Both pa-
tients had a strong clinical history of PCD, one with SI.
The PCD diagnostics for the first case revealed abnormal
nNO, most IDAs missing, normal CBF and subtle CBP
abnormalities. The second case had normal CBF, 20%
dyskinetic and normal TEM. These cases highlight the
importance of genetics to help establish a diagnosis – es-
pecially if there is a strong clinical suspicion when other
investigations are inconclusive [44].
Rob Hirst (UK) presented a 9 year old African boy
with severe respiratory disease from 12 months, ear in-
fections, atopy and clubbing. PCD work-up demon-
strated dyskinetic cilia, normal CBF with whip-like
motion occasionally, long cilia and expanded sections of
cilia shafts (also after culture). TEM revealed long “cobra
head” cilia with a normal axoneme structure. The pa-
tient died of pneumonia before work-up was completed.
The group concluded that he likely had a ciliopathy. The
audience was not aware of “cobra-head” cilia previously
reported in the literature.
Louise Hughes (Australia) and Lucy Morgan (Australia)
presented a patient with a strong PCD clinical phenotype,Fig. 2 Country of work of respondents of the feedback survey for the 3rd B
ASR: advanced stage researcherlow nNO, and reduced CBF (<5 Hz). TEM and IF were
abnormal and revealed two subgroups of cilia. There was
a clear deficiency of IDA in isolation (i.e. not occurring in
combination with an ODA defect, or with microtubular
disarray), despite abnormal staining with DNAH5 and
GAS8 markers. The group agreed that there was a possi-
bility of both defects co-existing.
Nicola Ullman (Italy) presented a 10 year old child
born with oesophageal atresia type IIIC and dextrocar-
dia, who suffered from chronic vomiting and respiratory
symptoms post-operatively. A CT scan showed severe
bronchiectasis with parenchymal destruction of right
lower and middle lobes. PCD diagnostics showed only
reduced cilia motility (6.3Hz) and genetics revealed two
heterozygous mutations in two different genes, DNAH8
and DNAAF5; both maternally inherited, and mother
was clinically well. The audience discussed that DNAH8
is not a respiratory ciliary gene and PCD diagnosis re-
quires bi-allelic mutations in one gene [41]. The audi-
ence attributed the bronchiectasis to aspiration and that
PCD was very unlikely.
Jane Lucas (UK) presented a case with normal nNO, ab-
normal TEM showing some cilia with absent central ap-
paratus, others with transposition defects and others with
normal ultrastructure. A second TEM sample was entirely
normal. HSVA demonstrated rotating cilia on that occa-
sion. Genetics revealed a mutation in RSPH1 [45–47].
This case demonstrated that non-hallmark cilia ultrastruc-
ture defects can change. This also serves as an example of
a PCD case with nNO within the normal range.
Early stage researchers networking forum
The 1st Early Stage Researchers (ESR) networking forum
was held during the BEAT-PCD Training School, led by
ESR representatives Myrofora Goutaki (Switzerland) andEAT-PCD Conference & 4th Training School. ESR: Early stage researcher,
Fig. 3 Main expertise of respondents of the feedback survey for the 3rd BEAT-PCD Conference & 4th Training School. ENT: ear, nose and throat
specialist. The term “Researcher” includes epidemiologists; and “Other” includes pathologists, radiologists, microbiologists and
patient representatives
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event, including postgraduate students and postdoctoral
researchers, clinicians, and healthcare professionals. The
ESR representatives highlighted several prospects for
ESR to participate in the BEAT-PCD network activities.
These include: developing the e-newsletter; organising
the conference; chairing sessions; and writing the confer-
ence proceedings. STSMs were highlighted as a unique
opportunity for ESR to learn new skills, develop joint
projects and work collaboratively with other PCD
groups. The application process was explained and par-
ticipants heard from previous researchers who have
completed STSMs.
Twenty-two participants completed a feedback survey
(50% response rate). Respondents rated the networking
forum 8 out 10 and all of those that completed the sur-
vey requested a 2nd ESR networking forum at the next
BEAT-PCD Training School. The majority of respon-
dents expressed an interest in discussing the following
topics at future ESR events: project design and manage-
ment; writing a grant application; and small breakout
groups to discuss collaborative projects.
Evaluation feedback from participants
An online feedback survey was circulated to participants
following the Conference and Training School. Seventy-six
respondents (61% response rate) from 19 countries com-
pleted the survey (Fig. 2). Half of the respondents were
ESR, of which 53% had attended previous BEAT-PCD Con-
ferences [9].
Participants highlighted the opportunity to network
with experts from varied backgrounds (Fig. 3) and PCD
research groups as one of the best features of the Confer-
ence, along with the plenary talks, oral presentations and
difficult case discussions. A third of ESR stressed that theTraining School interactive workshops were their pre-
ferred activity.
Both ESR and Advanced Stage Researchers (ASR) rated
the event 9 out of 10, with 92% of respondents’ stating that
the Conference and Training School met their expecta-
tions and addressed their needs.
Summary
The BEAT-PCD Conference and Training school brought
together clinical specialists (paediatricians and adult pul-
monologists, ENT, physiotherapists, specialist nurses) and
scientists from varied backgrounds (PCD diagnostics, gen-
etics, imaging, cell biology, microbiology, bioinformatics).
This multidisciplinary conference continues to provide an
interactive platform for clinicians and researchers from
andpromotes the exchange of ideas through a programme
of lectures, poster sessions, workshops and discussions.
The next BEAT-PCD conference and training school will
be held in Poland in 2019.
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